Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy

Annals of Neurology

Volumn 57, Issue 2, 2005, Pages 252-257

  Pack, Alison M ^a   Morrell, Martha J ^a   Marcus, Robert ^b   Holloway, Leah ^c   Flaster, Edith ^a   Doñe, Silvia ^a   Randall, Alison ^a   Seale, Cairn ^b   Shane, Elizabeth ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; ANTICONVULSIVE AGENT; BINDING PROTEIN; CALCIUM; CARBAMAZEPINE; COLLAGEN TYPE 1; INSULIN BINING PROTEIN III; LAMOTRIGINE; OSTEOCALCIN; PARATHYROID HORMONE; PHENYTOIN; SOMATOMEDIN; UNCLASSIFIED DRUG; VALPROIC ACID;

ADULT; ARTICLE; BLOOD ANALYSIS; BONE DENSITOMETRY; BONE MASS; BONE METABOLISM; BONE TURNOVER; CONTROLLED STUDY; EPILEPSY; EXERCISE; FEMALE; HUMAN; MONOTHERAPY; NUTRITION; OSSIFICATION; POSTMENOPAUSE; PRIORITY JOURNAL; URINALYSIS;

ADOLESCENT; ADULT; ANTICONVULSANTS; BONE AND BONES; BONE REMODELING; CARBAMAZEPINE; EPILEPSY; FEMALE; HUMANS; MINERALS; PHENYTOIN; PREMENOPAUSE; VALPROIC ACID;

EID: 13144282677     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20378     Document Type: Article

References (34)

1. Marcus R. Secondary forms of osteoporosis. In: Coe FL, Favus MJ, eds. Disorders of bone and mineral metabolism. New York: Raven Press, 1992:889-904.
2. Pack AM, Olarte LS, Morrell MJ, et al. Bone mineral density in an outpatient population receiving enzyme-inducing antiepileptic drugs. Epilepsy Behav 2003;4:169-174.
3. Hahn TJ, Hendin BA, Scharp CR, Haddad JG Jr. Effect of chronic anticonvulsant therapy on serum 25-hydroxycalciferol levels in adults. N Engl J Med 1972;287:900-904.
4. Bouillon R, Reynaert J, Claes JH, et al. The effect of anticonvulsant therapy on serum levels of 25-hydtoxy-vitamin D, calcium, and parathyroid hormone. J Clin Endocrinol Metab 1975;41:1130-1135.
5. Gough H, Goggin T, Bissessar A, et al. A comparative study of the relative influence of different anticonvulsant drugs, UV exposure and diet on vitamin D and calcium metabolism in outpatients with epilepsy. Q J Med 1986;59:569-577.
6. O'Hare JA, Duggan B, O'Driscoll D, Callaghan N. Biochemical evidence for osteomalacia with carbamazepine therapy. Acta Neurol Scand 1980;62:282-286.
7. Bogliun G, Beghi E, Crespi V, et al. Anticonvulsant drugs and bone metabolism. Acta Neurol Scand 1986;74:284-288.
8. Hoikka V, Savolainen K, Esko M, Alhava EM. Osteomalacia in institutionalized epileptic patients on long-term anticonvulsant therapy. Acta Neurol Scand 1981;64:122-131.
9. Weinstein RS, Bryce GF, Sappington LJ, et al. Decreased serum ionized calcium and normal vitamin D metabolite levels with anticonvulsant drug treatment. J Clin Endocrinol Metab 1984;58:1003-1009.
10. Andress DL, Ozuna J, Tirschwell D, et al. Antiepileptic drug-induced bone loss in young male patients who have seizures. Arch Neurol 2002;59:781-786.
11. Valimaki MJ, Tiihonen M, Laitinen K, et al. Bone mineral density measured by dual-enetgy x-ray absorptiometry and novel markers of bone formation and resorption in patients on anti-epileptic drugs. J Bone Miner Res 1994;9:631-637.
12. Verrotti A, Greco R, Morgese G, Chiarelli F. Increased bone turnover in epileptic patients treated with carbamazepine. Ann Neurol 2000;47:385-388.
13. Sato Y, Kondo I, Ishida S, et al. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 2001;57:445-449.
14. Verrotti A, Greco R, Latini G, et al. Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine. Epilepsia 2002;43:1488-1492.
15. Schneider A, Shane E. Osteoporosis due to illness and medications. In: Marcus R, Feldman D, Kelsey J, eds. Osteoporosis. Vol 2. San Diego: Academic Press, 2001:303-326.
16. Sheth RD, Wesolowski CA, Jacob JC, et al. Effect of carbamazepine and valproate on bone mineral density. J Pediatr 1995;127:256-262.
17. Guo C-Y, Ronen GM, Atkinson SA. Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy. Epilepsia 2001;42:1141-1147.
18. Block G, Hartman AM, Dresser, CM, et al. A data-based approach to diet questionnaire design and testing. Am J Epidemiol 1986;124:453-469.
19. Katzman DK, Bachrach LK, Carter DR, Marcus R. Clinical and anthropometric correlates of bone mineral acquisition in healthy adolescent girls. J Clin Endocrinol Metab 1991;73:1332-1339.
20. Marcus R, Holloway L, Wells B, et al. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. J Bone Miner Res 1999;14:1583-1595.
21. Ghiron LJ, Thompson JL, Holloway L, et al. Effects of recombinant insulin-like growth factor-I and growth hormone on bone turnover in elderly women. J Bone Miner Res 1995;10:1844-1852.
22. Holloway L, Butterfield G, Hintz RL, et al. Effects of recombinant growth hormone on metabolic indices, body composition, and bone turnover in healthy elderly women. J Clin Endocrinol Metab 1994;79:470-479.
23. Delmas PD, Eastell R, Garnero P, et al. The use of biochemical markers of bone turnover in osteoporosis. Osteoporosis Int 2000;11(suppl 6):S2-S17.
24. Malabanan A, Veronikis IE, Holick MF. Redefining vitamin D insufficiency. Committee of Scientific Advisors of the International Osteoporosis Foundation. Lancet 1998;351:805-806.
25. Garnero P, Sornay-Rendu E, Clausrrat B, Delmas PD. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 2000;15:1526-1536.
26. Hannon RA, Eastell R. Biochemical markers of bone turnover and fracture prediction. J Br Menopause Soc 2003;9:10-15.
27. Mosekilde L, Melsen F. Dynamic differences in trabecular bone remodeling between patients after jejuno-ileal bypass for obesity and epileptic patients receiving anticonvulsant therapy. Metab Bone Dis Relat Res 1980;2:77-82.
28. Koch HV, Kraft D, von Herrath D, Schaefer K. Influence of diphenylhydantoin and phenobarbital on intestinal calcium transport in the rat. Epilepsia 1972;13:829-841.
29. Takahashi A, Onodera K, Shinoda H, Mayanagi H. Phenytoin and its metabolite, 5-(4-hydroxyphenyl)-5-phenylhydantoin, show bone resorption in cultured neonatal mouse calvaria. Jpn J Pharmacol 2000;82:82-84.
30. Onodera K, Takahashi A, Sakurada S, Okano Y. Effects of phenytoin and/or vitamin K2 (menatetrenone) on bone mineral density in the tibiae of growing rats. Life Sci 2002;70:1533-1542.
31. Hahn TJ, Scharp CR, Richardson CA. Interaction of diphenylhydantoin (phenytoin) and phenobarbital with hormonal mediation of fetal rat bone resorption in vitro. J Clin Invest 1978;62:406-414.
32. Vernillo AT, Rifkin BR, Hauschka PV. Phenytoin affects osteocalcin secretion from osteoblastic rat osteosarcoma 17/2.8 cells in culture. Bone 1990;11:309-312.
33. Hahn TJ, Hendin BA, Scharp CR, et al. Serum 25-hydroxy calciferol levels and bone mass in children on chronic anti-epileptic therapy. N Engl J Med 1975;292:550-554.
34. Stephen LJ, McLellan AR, Harrison JH, et al. Bone density and epileptic drugs: a case-controlled study. Seizure 1999;8: 339-342.